<DOC>
	<DOC>NCT02948842</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of clostridium histolyticum collagenase (XIAFLEX®) in treating urethral strictures.</brief_summary>
	<brief_title>Clostridium Histolyticum Collagenase Injection for Urethral Disease</brief_title>
	<detailed_description>This is an open-label, pilot study to explore the efficacy of clostridium histolyticum collagenase (XIAFLEX®) in treating urethral strictures. Subjects will be followed for 2 years from the initial drug treatment.</detailed_description>
	<mesh_term>Urethral Stricture</mesh_term>
	<mesh_term>Urethral Diseases</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Males Age ≥ 18 years Failed prior proven conservative measures, including DVIU or balloon dilation of the stricture will be included in this study Able and willing to undergo regular intervention as well as evaluation as described below will be included in the study With a single stricture &lt;2cm in size that can be identified on retrograde urethrogram or voiding cystourethrogram will be included in the study. Must agree not to participate in a clinical study involving another investigational drug or device throughout the duration of this study Must be competent to understand the information given in IRB approved ICF and must sign the form prior to the initiation of any study procedure Has not yet undergone proven noninvasive measures, including DVIU or balloon dilation. Multiple strictures or a single stricture larger than 2cm in size, measured with retrograde urethrogram or voiding cystourethrogram. Age &lt;18 Females Prior urethroplasty Urethral fistula Allergy or sensitivity to CHC Bleeding disorder or anticoagulant use other than aspirin up to 150mg/day Untreated urinary tract infection Inability to perform intermittent selfcatheterization Participation in another clinical study or treatment with an investigational drug or device Serious or active medical or psychiatric condition which, in the opinion of the Investigator, may interfere with treatment, assessment, or compliance with the protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>